bay1251152
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 10, 2016 (NCT02635672)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bay1251152
- bay 1251152
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05371054 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT04978779 | Phase 1 | Aug 31, 2021 | Vincerx Pharma, Inc. |
| NCT02745743 | Phase 1 | Jun 17, 2016 | Bayer |
| NCT02635672 | Phase 1 | Feb 10, 2016 | Bayer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 2 | 2 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2022 |
| Vincerx Pharma, Inc. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1